Mai 6, 2023

Exclusive License to novel nanoparticle delivery technology

We have reached agreement with beniag GmbH and have exclusively in-licensed their proprietary Fusogenic Liposome technology and know-how for the delivery of RNAs in vivo.

Delivery of nucleic acids by systemic application is a key hurdle and is preventing novel therapies to be developed faster and more efficient. Fusogenic Liposomes will enable us to pre-target our seRNAs to organs and tissues of interest and thus help us to overcome this challenge. 

This will lead to the faster, more efficient development of seRNAs thereby supporting our efforts to bring seRNAs to patients in some of the most devastating diseases.